Ciprofloxacin
- Generic Name
- Ciprofloxacin
- Brand Names
- Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18FN3O3
- CAS Number
- 85721-33-1
- Unique Ingredient Identifier
- 5E8K9I0O4U
- Background
Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.
The first ciprofloxacin containing product was FDA approved on 22 October 1987.
- Indication
Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.
A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa. Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa. A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.
A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis. A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.
A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.
- Associated Conditions
- Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae
Antibiotic Treatment foLlowing Surgical drAinage of Perianal abScess; the ATLAS Trial
- Conditions
- Perianal FistulaDrain AbscessPerianal Abscess
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- dr. IJM Han-Geurts
- Target Recruit Count
- 298
- Registration Number
- NCT05385887
- Locations
- 🇳🇱
Rode Kruis ziekenhuis, Beverwijk, Noord-Holland, Netherlands
🇳🇱Dijklander hospital, Hoorn, North-Holland, Netherlands
🇳🇱Proctos kliniek, Bilthoven, Utrecht, Netherlands
Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
- Conditions
- Gonorrhea Male
- Interventions
- Biological: Neisseria gonorrhoeae strain FA1090Biological: Tetanus-diptheria Vaccine
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 140
- Registration Number
- NCT05294588
- Locations
- 🇺🇸
Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North, Chapel Hill, North Carolina, United States
🇺🇸Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North, Chapel Hill, North Carolina, United States
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
- Conditions
- Neisseria Gonorrhoeae Infection
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1800
- Registration Number
- NCT05286931
- Locations
- 🇺🇸
Public Health -- Seattle & King County Sexual Health Clinic, Seattle, Washington, United States
The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects
- Conditions
- Nasal and Pharyngeal Microbiome
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 20
- Registration Number
- NCT05287425
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Role of Prophylactic Postoperative Antibiotics in HoLEP
- Conditions
- Urinary Tract InfectionsBenign Prostatic Hyperplasia
- Interventions
- Procedure: Holmium Laser Enucleation of prostate
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05274672
- Locations
- 🇺🇸
Einstein Healthcare network, Philadelphia, Pennsylvania, United States
🇺🇸Baylor Scott and White, Temple, Texas, United States
A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05232461
- Locations
- 🇺🇸
Novum, Fargo, North Dakota, United States
Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial
- Conditions
- MoxifloxacinPost-Traumatic EndophthalmitisEndophthalmitisOpen Globe Injury
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 100
- Registration Number
- NCT05162625
- Locations
- 🇧🇷
University of Campinas, Campinas, Brazil
Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan
- Conditions
- Bacterial InfectionsAntibiotic Resistant InfectionSurgical Site Infection
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Yarmouk University
- Target Recruit Count
- 24
- Registration Number
- NCT05106803
- Locations
- 🇯🇴
Yarmouk University, Irbid, Jordan
Collaborative Urological Prosthetics Investigation Directive Research Group
- Conditions
- Erectile DysfunctionPenile Prosthesis Infection
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 800
- Registration Number
- NCT05100654
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
- Conditions
- Febrile Neutropenia
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 312
- Registration Number
- NCT04948463
- Locations
- 🇦🇺
Royal Children's Hospital, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.